哌啶-2-羧酸盐酸盐 | 15862-86-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 哌啶-2-羧酸盐酸盐
• 英文名称: piperidine-2-carboxylic acid hydrochloride
• 英文别名: (S)-piperidine-2-carboxylic acid ; hydrochloride；(+/-)-Piperidin-2-carbonsaeure; Hydrochlorid；(S)-Piperidin-2-carbonsaeure; Hydrochlorid；pipecolic acid hydrochloride；hydron;piperidine-2-carboxylic acid;chloride
• CAS: 15862-86-9
• 化学式: C₆H₁₁NO₂*ClH
• mdl: MFCD00012771
• 分子量: 165.62
• InChiKey: AUGDEGXARBUSFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.12
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  49.3
• 氢给体数：
  3
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  哌啶-2-羧酸盐酸盐 在 五氯化磷 、 乙酰氯 作用下， 反应 7.0h， 生成 2-哌啶羰基氯化物
  参考文献：
  名称：

  Synthesis of 2-piperidinecarboxylic acid derivatives as potential anticonvulsants

  摘要：

  A variety of 2-piperidinecarboxamides were synthesized and evaluated for anticonvulsant activity using the MES and sc PTZ tests in mice and rats. Neurotoxicity was determined by the rotorod test. Several N-(benzyl)-2-piperidinecarboxamides exhibited potent MES activity in mice [2-CF3 14, ED50 = 29 mg/kg; 3-F 16, ED50 = 31 mg/kg; and 3-CF3 17, ED50 = 24 mg/kg]. The most active compounds in the MES test in mice were the 2,6-dimethylanilides [(R,S)-34, ED50 = 5.8 mg/kg; (R)-35, ED50 = 5.7 mg/kg; and (S)-36, ED50 = 14.8 mg/kg]. The enantiomer (S)-36 was about two-fold less potent in the MES test than (R)-35 and also was less neurotoxic. Acylation of the piperidine ring nitrogen of 12 and 34 led to a decrease in the MES activity. In the N-(alpha-methylbenzyl)-2-piperidine-carboxamides, the stereochemistry at either the 2-position of the piperidine ring or at the alpha-position of the N-(alpha-methylbenzyl) group does not significantly affect MES activity. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80072-5
• 作为产物：
  描述：

  methyl 2,6-dibromohexanoate 在 苄基三乙基氯化铵 氢氧化钾 、 potassium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 24.0h， 生成 哌啶-2-羧酸盐酸盐
  参考文献：
  名称：

  Synthesis of 2-amino acids via selective mono-N-alkylation of trichloroacetamide by 2-bromo carboxylic esters under solid-liquid phase-transfer catalysis conditions

  摘要：

  DOI：

  10.1021/jo00031a052

文献信息

• [EN] BORONIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE BORONIQUE
  申请人：MERCK PATENT GMBH

  公开号：WO2016050358A1

  公开（公告）日：2016-04-07

  Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmue disorder or hematological malignancies.

  式(I)的化合物是LMP7的抑制剂，可用于治疗自身免疫性疾病或血液恶性肿瘤，等等。
• [EN] PROCESS FOR PRODUCING PIPECOLIC-2-ACID-2 ',6'-XYLIDIDE USEFUL AS AN INTERMEDIATE FOR THE PREPARATION OF LOCAL ANESTHETICS<br/>[FR] PROCÉDÉ DE PRODUCTION D'ACIDE-2-PIPÉCOLIQUE-2',6'-XYLIDIDE UTILE EN TANT QU'INTERMÉDIAIRE POUR LA PRÉPARATION D'ANESTHÉSIQUES LOCAUX
  申请人：PHARMATHEN SA

  公开号：WO2009089842A1

  公开（公告）日：2009-07-23

  The present invention relates to an improved process for the preparation of pipecolic-2- acid-2',6'-xylidide or derivative thereof wherein it comprises hydrogenation of picolinic-2-acid-2',6'-xylidide in the presence of a Raney-nickel as a catalyst.

  本发明涉及一种改进的制备pipolic-2-酸-2',6'-xylidide或其衍生物的方法，其中它包括在存在Raney镍作为催化剂的情况下对picolinic-2-酸-2',6'-xylidide进行氢化。
• 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물
  申请人：The Industry & Academic Cooperation in Chungnam National University (IAC) 충남대학교산학협력단(220040084104) BRN ▼314-82-09264

  公开号：KR101555033B1

  公开（公告）日：2015-09-23

  본 발명은 신규한 메타논 유도체, 이의 제조방법, 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물에 관한 것으로, 본 발명에 따른 신규한 메타논 유도체, 이의 광학 이성질체, 또는 이의 약학적으로 허용가능한 염은 RIPK1(Receptor-interacting serine/threonine-protein kinase 1)의 억제 효과가 뛰어나므로, 이를 유효성분으로 함유하는 조성물은 색소성 망막염 (RP), 레베르 선천 흑암시 (LCA), 스타가르트병, 어셔 증후군, 맥락막 결여, 로드-콘 또는 콘-로드 디스트로피, 섬모병증, 미토콘드리아 장애, 진행성 망막 위축증, 퇴행성 망막 질환, 노화-관련된 황반 변성 (AMD), 습성 AMD, 건성 AMD, 지도상 위축증, 가족형 또는 획득 황반병증, 망막 광수용체 질환, 망막 색소 상피-계 질환, 당뇨병성 망막증, 낭포성 황반 부종, 포도막염, 망막박리, 외상성 망막 손상, 의원성 망막 손상, 황반 원공, 황반 모세관확장증, 신경절 세포 질환, 시신경 세포 질환, 녹내장, 시신경병증, 허혈성 망막 질환, 미숙아 망막증, 망막 혈관 폐색, 가족형 마크로아뉴리즘, 망막 혈관 질환, 안혈관 질환, 녹내장으로 인한 망막신경세포 퇴화, 또는 허혈성 시신경병증 등의 망막 질환의 예방 또는 치료용 약학적 조성물로 유용하게 사용될 수 있다.

  本发明涉及一种新型的甲酮衍生物，其制备方法，以及用作视网膜疾病的预防或治疗药物组合物，根据本发明，由于新型的甲酮衍生物，其光学异构体或药学上可接受的盐具有出色的RIPK1（受体相互作用丝氨酸/苏氨酸蛋白激酶1）抑制作用，因此包含其作为有效成分的组合物可用作色素性视网膜炎（RP），勒贝尔先天性黑暗症（LCA），斯塔加特病，阿什尔综合征，脉络膜缺陷，罗德-锥或锥-罗德萎缩症，圆锥细胞病，线粒体疾病，进行性视网膜萎缩症，变性性视网膜疾病，与衰老相关的黄斑变性（AMD），湿性AMD，干性AMD，地图样萎缩症，家族性或获得性黄斑病变，视网膜光感受器疾病，视网膜色素上皮相关疾病，糖尿病性视网膜病变，囊性黄斑水肿，葡萄膜炎，视网膜脱离，创伤性视网膜损伤，原发性视网膜损伤，黄斑囊肿，黄斑脉络膨胀症，神经节细胞疾病，视神经细胞疾病，青光眼，视神经病变，缺血性视网膜疾病，未成熟婴儿视网膜病变，视网膜血管闭塞，家族性巨动脉瘤，视网膜血管疾病，眼内血管疾病，由青光眼引起的视神经细胞退化，或缺血性视神经病变等视网膜疾病的预防或治疗药物组合物可被有效地使用。
• COMPOUNDS USEFUL AS IMMUNOMODULATORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20170107202A1

  公开（公告）日：2017-04-20

  The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical compositions comprising at least one compound according to the disclosure that are useful for the treatment of various diseases, including cancer and infectious diseases.

  本发明公开一般涉及可用作免疫调节剂的化合物。本发明提供了化合物、包含此类化合物的组合物及其使用方法。本发明还涉及包含至少一种根据本发明的化合物的药物组合物，这些药物组合物可用于治疗各种疾病，包括癌症和传染病。
• [EN] S1P MODULATING AGENTS<br/>[FR] AGENTS MODULANT S1P
  申请人：BIOGEN IDEC INC

  公开号：WO2012109108A1

  公开（公告）日：2012-08-16

  Compounds of formula (I) or (II) can modulate the activity of SIP receptors.

  化合物的分子式（I）或（II）可以调节SIP受体的活性。

表征谱图